# A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients

Study · id `cardio:ct-nct07930507` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07930507](<https://clinicaltrials.gov/study/NCT07930507>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07930507

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 204 participants.

## Technical summary

Registry record NCT07930507. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-21 (anticipated); primary completion 2027-10-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 204 participants (planned count; ClinicalTrials.gov record NCT07930507, source copy `cardio:ctgov-nct07930507-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-12-21 (anticipated) (ClinicalTrials.gov record NCT07930507, source copy `cardio:ctgov-nct07930507-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2027-10-11 (anticipated) (ClinicalTrials.gov record NCT07930507, source copy `cardio:ctgov-nct07930507-2026-11-12`, retrieved 2026-11-18)
- Completion: 2027-10-11 (anticipated) (ClinicalTrials.gov record NCT07930507, source copy `cardio:ctgov-nct07930507-2026-11-12`, retrieved 2026-11-18)
- Countries: China; Hong Kong SAR China; Malaysia; South Korea; Thailand; Vietnam (ClinicalTrials.gov record NCT07930507, source copy `cardio:ctgov-nct07930507-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07930507-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
- Condition: Hypercholesterolemia
- Intervention (Drug): Laroprovstat
- Intervention (Drug): Rosuvastatin 1
- Intervention (Drug): Rosuvastatin 2
- Intervention (Drug): FDC laroprovstat/Rosuvastatin 1
- Intervention (Drug): FDC laroprovstat/Rosuvastatin 2
- Intervention (Drug): Placebo to match rosuvastatin
- Intervention (Drug): Placebo to match laroprovstat or FDC laroprovstat/rosuvastatin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: e959f03fc40314988a41727dfed6066640ab058a074753a55aba0cb1d5774039
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
